Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
Pre-surgical, window-of-opportunity trials provide a suitable model to assess the activity of preventive interventions in a cost-effective manner using tissue biomarkers as surrogate endpoints. Finasteride has been shown to reduce prostate cancer development in a large phase III trial, and flutamide has a well-known anticancer effect in advanced prostate cancer at the dose of 750 mg/day.
Epistemonikos ID: 675fba4a9d5f2e6767cf9ae4f6d82140edb81f2b
First added on: Apr 17, 2025